PL2034970T3 - Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę - Google Patents

Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę

Info

Publication number
PL2034970T3
PL2034970T3 PL07777373T PL07777373T PL2034970T3 PL 2034970 T3 PL2034970 T3 PL 2034970T3 PL 07777373 T PL07777373 T PL 07777373T PL 07777373 T PL07777373 T PL 07777373T PL 2034970 T3 PL2034970 T3 PL 2034970T3
Authority
PL
Poland
Prior art keywords
phenylephrine
sustained release
pharmaceutical formulation
release pharmaceutical
formulation
Prior art date
Application number
PL07777373T
Other languages
English (en)
Polish (pl)
Inventor
David Monteith
John O'mullane
Joseph P Reo
Robert T Nowak
Jiansheng Wan
Mohammed A Kabir
Malaz A Abutarif
Glenn E Fritz
Original Assignee
Msd Consumer Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38659360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2034970(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Msd Consumer Care Inc filed Critical Msd Consumer Care Inc
Publication of PL2034970T3 publication Critical patent/PL2034970T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07777373T 2006-06-01 2007-06-01 Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę PL2034970T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81002106P 2006-06-01 2006-06-01
US87483006P 2006-12-14 2006-12-14
EP07777373A EP2034970B1 (en) 2006-06-01 2007-06-01 Sustained release pharmaceutical formulation comprising phenylephrine
PCT/US2007/013050 WO2007143158A2 (en) 2006-06-01 2007-06-01 Sustained release pharmaceutical formulation comprising phenylephrine

Publications (1)

Publication Number Publication Date
PL2034970T3 true PL2034970T3 (pl) 2012-12-31

Family

ID=38659360

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07777373T PL2034970T3 (pl) 2006-06-01 2007-06-01 Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę

Country Status (20)

Country Link
US (2) US8956662B2 (https=)
EP (2) EP2366381A1 (https=)
JP (2) JP5175278B2 (https=)
KR (1) KR101643626B1 (https=)
CN (1) CN104161736A (https=)
AR (1) AR061169A1 (https=)
AU (1) AU2007254821B2 (https=)
BR (1) BRPI0712532A2 (https=)
CA (1) CA2653953C (https=)
CL (1) CL2007001584A1 (https=)
ES (1) ES2391585T3 (https=)
MX (1) MX2008015360A (https=)
NO (1) NO20085420L (https=)
NZ (1) NZ573173A (https=)
PE (1) PE20080151A1 (https=)
PL (1) PL2034970T3 (https=)
RU (1) RU2454225C2 (https=)
SG (1) SG172664A1 (https=)
TW (1) TWI411451B (https=)
WO (1) WO2007143158A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
JP2010510320A (ja) 2006-11-21 2010-04-02 マクニール−ピーピーシー・インコーポレーテツド 改変型放出鎮痛性懸濁液
CN101848706A (zh) * 2007-06-01 2010-09-29 先灵-普劳健康护理产品公司 包含底物和含活性成分和聚乙烯醇的包衣的药用组合物
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
US20110150945A1 (en) * 2008-08-11 2011-06-23 Mepha Gmbh Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
MX2009001925A (es) * 2009-02-20 2010-08-20 Senosiain S A De C V Lab Composicion farmaceutica oral para uso en enfermedades respiratorias.
PE20142043A1 (es) * 2011-09-27 2014-12-18 Univ Virginia Commonwealth Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
RU2540509C1 (ru) * 2013-02-04 2015-02-10 АФТ Фармасьютиклс Лтд Лекарство
ITMI20132066A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali
WO2016015814A1 (de) 2014-07-30 2016-02-04 Merck Patent Gmbh Pulverförmige, direkt verpressbare polyvinlalkohol-typen
CA2956538C (en) * 2014-07-30 2023-01-03 Merck Patent Gmbh Directly compressible composition comprising microcrystalline cellulose
AU2015317469B2 (en) * 2014-09-19 2018-03-15 The Procter & Gamble Company Pulsed release phenylephrine dosage forms
GB201420306D0 (en) * 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
BR112018069440A2 (pt) 2016-03-25 2019-02-12 Univ Gent forma de dosagem oral
US10966928B2 (en) 2016-03-25 2021-04-06 Universiteit Gent Oral dosage form
KR20190026648A (ko) * 2016-03-30 2019-03-13 바이탈 베버리지스 글로벌 인크. 선택적 위장관 전달을 위한 조성물 및 방법
US10278930B2 (en) * 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
WO2019030284A1 (en) * 2017-08-09 2019-02-14 Helmholtz-Zentrum für Infektionsforschung GmbH NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF
EP3622948A1 (en) 2018-09-11 2020-03-18 I.P.S. International Products & Services S.r.l. Multilayered formulations with dual release rate of one or more active principles
JP7263047B2 (ja) * 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (https=) 1963-04-24
US3419565A (en) 1963-04-24 1968-12-31 Schering Corp Aza-dibenzocycloheptenes
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US3559768A (en) * 1969-12-22 1971-02-02 Henry P Cox Emergency elevator evacuation of tall buildings
US3851051A (en) * 1970-07-17 1974-11-26 Scherer R Corp Soft gelatin capsule containing high water content fill
US3696188A (en) * 1971-06-16 1972-10-03 Schering Corp Laminated tablets
US3878217A (en) 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4219559A (en) 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
DK154078C (da) 1981-02-06 1989-05-22 Ucb Sa Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
WO1985003707A1 (en) * 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US5025019A (en) * 1984-04-09 1991-06-18 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
EP0208855B1 (en) 1985-05-13 1991-03-06 Schering Corporation process for preparing piperidylidene dihydrodibenzo(a,d)cycloheptenes and aza derivatives thereof, compounds obtained by such process and the use of such compounds for preparing useful pharmaceutical compositions
US4623664A (en) * 1985-10-31 1986-11-18 University Of Iowa Research Foundation Oil suspended phenylephrine
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
JPH0794379B2 (ja) * 1990-08-07 1995-10-11 ファイザー・インコーポレーテッド 放出製剤における界面重合膜の使用方法
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
GB9402203D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
CN1235545A (zh) * 1996-10-31 1999-11-17 先灵公司 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
MX9701946A (es) * 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
IL135258A0 (en) * 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6521254B2 (en) * 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
AU2697100A (en) 1999-02-23 2000-09-14 Yuhan Corporation Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
WO2001089476A1 (en) * 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030083354A1 (en) * 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US20030114535A1 (en) * 2001-12-14 2003-06-19 Jame Fine Chemicals, Inc. Dextrochlorpheniramine tannate
CN101352421A (zh) 2002-01-16 2009-01-28 贝林格尔英格海姆法玛两合公司 一种制备基本上非结晶形式的替米沙坦的方法
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US20030175342A1 (en) * 2002-03-14 2003-09-18 Karl Kolter Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate
US20030203027A1 (en) * 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
RU2220740C1 (ru) 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Средство для лечения аллергического ринита и аллергического конъюнктивита
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US6979689B2 (en) * 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
JP2008523044A (ja) * 2004-12-13 2008-07-03 マクニール−ピーピーシー・インコーポレーテツド 医薬品有効成分を安定化する組成物および方法
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20080248107A1 (en) 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) * 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
JP2010510320A (ja) 2006-11-21 2010-04-02 マクニール−ピーピーシー・インコーポレーテツド 改変型放出鎮痛性懸濁液
US7378082B1 (en) * 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects

Also Published As

Publication number Publication date
EP2366381A1 (en) 2011-09-21
CN104161736A (zh) 2014-11-26
NZ573173A (en) 2012-03-30
CA2653953A1 (en) 2007-12-13
PE20080151A1 (es) 2008-02-25
JP5175278B2 (ja) 2013-04-03
US20150290147A1 (en) 2015-10-15
SG172664A1 (en) 2011-07-28
EP2034970B1 (en) 2012-08-01
KR20090014392A (ko) 2009-02-10
WO2007143158A3 (en) 2008-11-27
AR061169A1 (es) 2008-08-06
BRPI0712532A2 (pt) 2013-04-02
NO20085420L (no) 2008-12-30
AU2007254821B2 (en) 2013-11-14
TWI411451B (zh) 2013-10-11
US20080020055A1 (en) 2008-01-24
JP2009538920A (ja) 2009-11-12
US8956662B2 (en) 2015-02-17
CA2653953C (en) 2015-12-08
CL2007001584A1 (es) 2008-01-25
JP2013006878A (ja) 2013-01-10
KR101643626B1 (ko) 2016-07-29
AU2007254821A1 (en) 2007-12-13
WO2007143158A2 (en) 2007-12-13
MX2008015360A (es) 2009-03-06
ES2391585T3 (es) 2012-11-28
TW200815050A (en) 2008-04-01
EP2034970A2 (en) 2009-03-18
RU2454225C2 (ru) 2012-06-27
HK1121970A1 (en) 2009-05-08
RU2008151949A (ru) 2010-07-20

Similar Documents

Publication Publication Date Title
PL2034970T3 (pl) Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę
GB2450753B (en) New Pharmaceutical formulation
IL190499A0 (en) Sustained release small molecule drug formulation
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
HUE047394T2 (hu) Nyújtott hatóanyagleadású, poloxamert tartalmazó gyógyászati készítmények
EP2119442A4 (en) PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
IL188964A0 (en) Sustained drug release composition
ZA200705530B (en) Sustained release pharmaceutical formulations
ZA200808489B (en) Nicotine-carrier vaccine formulation
SI2180882T1 (sl) Trdni matriksni farmacevtski pripravek
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
GB0614586D0 (en) Pharmaceutical Formulation
PL2002828T3 (pl) Stały preparat farmaceutyczny
IL208788A (en) Pharmacy-based formulation
EP2211847A4 (en) PHARMACEUTICAL FORMULATION WITH CONTROLLED RELEASE
ZA200904654B (en) Tablet formulation
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
IL198160A0 (en) Pharmaceutical formulations
EP1871348A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE
GB0612556D0 (en) Topical pharmaceutical formulations
HK1121388A (en) Sustained release pharmaceutical dosage form containing phenylephrine
HU0700172D0 (en) Sustained release pharmaceutical preparation
IL178378A0 (en) Extended release pharmaceutical compositions
ZA201001127B (en) Pharmaceutical formulation for extended release